{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-049338","form_type":"8-K","ticker":"CTXR","cik":"0001506251","company_name":"Citius Pharmaceuticals, Inc.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.385386+00:00","generated_at":"2026-05-15T01:46:45.957587+00:00","sec_items":["3.02","1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius Oncology ships first international order of LYMPHIR to Europe","bullets":["First international shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through a regional distribution partner.","Product will be available via Named Patient Programs under applicable local regulations.","LYMPHIR approved by FDA in August 2024 for relapsed/refractory CTCL; U.S. commercial launch in December 2025.","Citius Oncology (Nasdaq: CTOR) is a majority-owned subsidiary of Citius Pharmaceuticals (CTXR).","International expansion complements ongoing U.S. launch progress with formulary access and payer coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-049338","json":"https://secwatch.observer/filing/0001213900-26-049338.json","markdown":"https://secwatch.observer/filing/0001213900-26-049338.md","text":"https://secwatch.observer/filing/0001213900-26-049338.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026049338/0001213900-26-049338-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506251/000121390026049338/ea0288203-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:46:45.957587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}